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Sympathetic hyperactivity in chronic kidney disease: Pathogen-
esis, clinical relevance, and treatment. Cardiovascular morbidity
and mortality importantly influence live expectancy of patients
with chronic renal disease (CKD). Traditional risk factors are
usually present, but several other factors have recently been
identified. There is now evidence that CKD is often character-
ized by an activated sympathetic nervous system. This may con-
tribute to the pathogenesis of renal hypertension, but it may also
adversely affect prognosis independently of its effect on blood
pressure. The purpose of this review is to summarize available
knowledge on the role of the sympathetic nervous system in the
pathogenesis of renal hypertension, its clinical relevance, and
the consequences of this knowledge for the choice of treatment.
Hypertension is common in patients with chronic kid-
ney disease (CKD). Its prevalence varies between 30%
and 100% depending on the target population, cause of
renal disease. and level of renal function [1]. Tradition-
ally this hypertension has been viewed as largely volume-
dependent. More than three decades ago, Kim et al [2]
showed that hypertensive and normotensive hemodialy-
sis patients differ in peripheral vascular resistance and not
in cardiac output. Importantly, after bilateral nephrec-
tomy blood pressure was reduced by a decrease in re-
sistance and not in cardiac output. This provided direct
evidence that the diseased kidneys were somehow in-
volved in the genesis of increased vascular resistance and
therefore hypertension in chronic renal failure (CRF).
There is now evidence that CKD is often character-
ized by an activated sympathetic nervous system. This
may contribute to the pathogenesis of renal hyperten-
sion, but it may also adversely affect prognosis indepen-
dently of its effect on blood pressure. This could have
important implications for the choice of treatment. The
Key words: renal hypertension, kidney disease, sympathetic activity,
angiotensin II, review.
Received for publication August 29, 2003
and in revised form October 8, 2003
Accepted for publication October 28, 2003
C© 2004 by the International Society of Nephrology
purpose of this review is to summarize available knowl-
edge on the role of the sympathetic nervous system in the
pathogenesis of renal hypertension, its clinical relevance,
and the consequences of this knowledge for the choice of
treatment.
MEASUREMENT OF SYMPATHETIC
NERVOUS ACTIVITY
The sympathetic nervous system is a part of the au-
tonomic nervous system. Its activity can be derived
indirectly from sympathetic effector responses, for in-
stance, blood pressure or heart rate. However, this is
very nonspecific, because effectors may also be influenced
by mechanical, chemical, and hormonal stimuli. Nore-
pinephrine that appears in the plasma is the net result of
discharge, reuptake, metabolism, and clearance, and as a
consequence is not suitable as marker for activity.
Several of these limitations can be overcome by the
use of sympathetic nerve recordings. True sympathetic
nerve activity can be assessed by the microneurographic
technique, which was developed by Vallbo et al [3]. The
intraneural recording is made with a tungsten microelec-
trode with a shaft of 0.2 mm and a tip of a few micrometers
placed in a peripheral nerve, generally the peroneal or ra-
dial nerve (muscle sympathetic nerve activity) (MSNA).
Usually, nerve recordings cause minimal discomfort and
negligible, transient after-effects, when studies are done
by an experienced technician. However, the technique is
not suitable for routine use, because it is laborious, time-
consuming, and technically difficult [4]. Figure 1 shows
typical examples of nerve recordings in humans.
The sympathetic nervous system is particularly rel-
evant for the short-term regulation of blood pressure.
Because the within-subject reproducibility of the basal
supine MSNA signal is very good, this technique has also
extensively been used to quantify chronic effects of inter-
ventions, such as medication or diet changes.
There are regional differences between sympathetic
activity in the human body. MSNA represents the cen-
trally generated postganglionic sympathetic activity to
the human skeletal muscle circulation, which is an
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Fig. 1. Typical examples of microneurographic assessment of muscle
sympathetic nerve activity (MSNA) in the peroneal nerve. The upper
tracing is a recording of a normal person and the lower tracing of a pa-
tient with chronic kidney disease. Each peak represents a spontaneous
burst of sympathetic nerve discharge. The rate of sympathetic nerve
discharge in the patient is much higher than in the age-matched healthy
control. Blood pressure curves (finger blood pressure) in the normal
person and the chronic kidney disease patient are shown as well.
important determinant of blood pressure [5, 6]. It does
not give information specifically about cardiac or renal
sympathetic activity. Isotopic dilution method for nore-
pinephrine spillover to plasma can be used for assess-
ment of organ-specific sympathetic activity, for instance
norepinephrine spillover into the cardiac, renal, or central
nervous system vascular bed [4]. Radionucleotide imag-
ing has been used to quantify cardiac sympathetic activity
[4].
PATHOGENESIS OF SYMPATHETIC
OVERACTIVITY IN CKD
Experimental studies
Renin-angiotensin system. Experimental studies have
come up with several pathophysiologic mechanisms
through which the diseased kidneys can be involved.
Inappropriate renin secretion in relation to the state
of sodium-volume balance has long been recognized [7].
The renin output of the kidney is the sum of the produc-
tion of all nephrons. If all nephrons of the diseased kid-
neys would have been affected equally and secrete equal
amounts of renin, CRF would be characterized as a new
steady-state with high blood pressure and normal renin.
However, this situation is uncommon, probably due to
the phenomenon of nephron heterogeneity, which stands
for the hypothesis that the disease does not equally affect
the nephrons. Those, which are severely affected, hypofil-
ter, and show impaired sodium excretion and renin hyper-
secretion, whereas those which are less affected will adapt
to the elevated blood pressure by hyperfiltering and sup-
pressing renin secretion. Blood pressure will not be high
enough to suppress renin production in all nephrons. As
a result, CRF is usually characterized by high blood pres-
sure and high renin. High circulating angiotensin II (Ang
II) has a variety of effects. Ang II is a direct vasoconstric-
tor, it increases aldosteron production, and it has trophic
effects. There is clear evidence that Ang II enhances sym-
pathetic activity, both at peripheral and central sites. It
directly stimulates MSNA, which indicates central sym-
pathetic activation [8]. It also enhances norepinephrine
release through a presynaptic effect [9]. This effect can
not be assessed by MSNA measurements. On the other
hand, sympathetic activation results in further activation
of the renin-angiotensin system [9].
Renal injury. Renal ischemia can lead to sympathetic
activation. During renal ischemia, adenosine is released.
This adenosine evokes an increase in afferent renal nerve
traffic, as can be shown during adenosine infusion in the
renal artery of uninephrectomized dogs [10]. In rats, in-
duction of renal artery stenosis [11], partial renal ablation
by arterial ligation [12] or intrarenal phenol injection [13]
cause excitation of the renal afferent nerves, which results
in neurogenic hypertension. Even a small injury in one
kidney caused by intrarenal injection of phenol, which
does not affect glomerular filtration rate (GFR), leads
to hypertension in association with an increased central
sympathetic activity [14]. In these animal models, renal
denervation results in a reduction or total prevention of
hypertension. Additionally, in the phenol hypertension
model, nephrectomy of the injured kidney several weeks
after the induction of renal damage results in normaliza-
tion of blood pressure [15]. Thus, renal injury in experi-
mental conditions can lead to sympathetic hyperactivity
and hypertension and this hyperactivity is associated with
activation of renal afferent nerves. The signal from the
diseased kidneys goes through the afferent renal nerves
to the central nervous system.
Nitric oxide inhibition. In animals, the sympathoexci-
tatory effect of nitric oxide inhibition has been clearly
demonstrated during systemic administration of nitric
oxide synthesis inhibitors and is greatly attenuated by
sympathectomy or by renal denervation [16, 17]. Basal
activity of central sympathetic activity is inhibited by
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central nitric oxide production [18]. Nitric oxide synthesis
inhibition by L-arginine analog N-nitro-L-arginine methyl
ester (L-NAME) results in an increase of central sym-
pathetic activity. The overall conclusion of experimental
studies is that nitric oxide has sympathoinhibitory and
vagotonic effects with attenuation of cardiovascular end-
organ responses, acting both on central and peripheral
mechanisms (review in [19]). In vivo and ex vivo ani-
mal experiments have provided evidence that neuronal
nitric oxide is a major component of the signal transduc-
tion pathway involved in the tonic restraint of central
sympathetic outflow [20]. In rats with CRF some specific
brain areas (i.e., posterior hypothalamic nuclei and the
locus coeruleus), which are involved in blood pressure
regulation by their effect sympathetic outflow, show a
greater turnover rate of norepinephrine, than control rats
[21].
In the phenol renal injury model neuronal nitric ox-
ide synthase (nNOS)-mRNA expression in brain areas
involved in noradrenergic control of blood pressure is
decreased as compared to controls. Intravenous adminis-
tration of losartan results in an increase of the abundance
of nNOS-mRNA in these brain nuclei [22]. These stud-
ies suggest that stimulation of the central sympathetic
nervous system activity by renal afferent impulses may
be mediated by local activation of Ang II, which stimu-
lates central sympathetic outflow by inhibition of NOS-
mRNA abundance. The sympatho-inhibitory effect of
intravenously administered losartan is mediated by
blockage of local Ang II, resulting in an up-regulation
of NOS-mRNA expression.
Clinical studies
It is long known that plasma catecholamine concen-
trations are approximately doubled in CRF patients [23,
24]. Application of the MSNA method has enhanced
our understanding of the pathogenesis of hypertension
in CKD patients. Although the MSNA technique was al-
ready available in the 1970s, the first publication show-
ing that MSNA was increased in CRF patients appeared
two decades later. Hemodialysis patients who still had
their native kidneys had elevated MSNA [25]. Subse-
quently, we and others confirmed these observations and
also showed that in hypertensive CRF patients not yet on
dialysis MSNA is increased [26, 27].
Renin-angiotensin system and renal injury. Converse
et al [25] studied bilaterally nephrectomized patients as
well and showed that MSNA was identical to healthy con-
trols, indicating that the signal that commands the brain
to increase sympathetic outflow is generated in the dis-
eased kidneys.
In another study, they provided data indicating that
baroreceptor function was not impaired [28]. We also
found no clear signs for baroreceptor dysfunction [26].
These human studies do not exclude the possibility of
subtle alteration of baroreceptor function, but they def-
initely exclude the presence of any relevant sino-aortic
or cardiopulmonary baroreceptor denervation (i.e., the
traditional notion of clinically important autonomic neu-
ropathy in CRF). Therefore, based on these studies,
sympathetic hyperactivity in CRF patients cannot by
explained on the basis of baroreceptor function
impairment.
Renal transplant patients with good renal graft func-
tion exhibit MSNA identical to hemodialysis patients
[27]. Bilateral nephrectomy in these transplant patients
resulted in a MSNA level not different from controls.
Furthermore, in human renovascular hypertension, an-
gioplasty resulted in a decrease of MSNA [29]. Unilateral
nephrectomy for transplantation purpose did not affect
MSNA [30]. All these data together indicate that in hu-
mans the diseased kidneys are also the key players in the
pathogenesis of increased MSNA.
Based on the experimental data outlined above, which
indicate that renal injury without affecting GFR can re-
sult in sympathetic hyperactivity, we hypothesized that
this would be also the case in humans. Normotensive
and hypertensive polycystic kidney disease (PKD) pa-
tients were investigated, either with normal renal func-
tion or with CRF. MSNA in hypertensive PKD patients
was increased regardless of renal function, whereas in
normotensive PKD patients MSNA was identical to con-
trols [31]. In this population, the MSNA correlated with
blood pressure, suggesting that the increased sympathetic
activity contributes to the pathogenesis.
A subsequent study was aimed to unravel the mecha-
nisms affecting the sympathetic nervous system in CKD
patients [30]. It has long been recognized that sympa-
thetic activity increases with age [32] and is feedback-
regulated by baroreflex control and volume status [33].
In CKD patients, volume status may vary substantially.
Therefore, it is critical that this should be taken into
account when assessing sympathetic activity in individ-
ual patients. We studied a large group of CKD patients
with various renal parenchymal diseases when in normo-
volemic condition, which was evidenced by assessment of
extracellular fluid volume (ECFV). On average MSNA
was higher in normovolemic patients than in controls.
Multiple regression analysis revealed age and plasma
renin activity as significant predictors for MSNA [30].
Figure 2 shows the relation between age and MSNA. Ad-
ditionally, both patients and controls were studied in two
different volume states (i.e., in patients when on and off
diuretics and in controls on high and low salt diet). The re-
lation between changes in volume and MSNA in patients
parallels that in healthy subjects, but is shifted to a higher
level of MSNA (Fig. 3). This relation is very similar to
that for volume and plasma renin activity. This similarity
suggests a cause-effect relation or a common origin.
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Fig. 2. Relation between age and muscle sympathetic nerve activity
(MSNA) (◦; controls, N = 57) (•; chronic kidney disease patients,
N = 57). In controls and in patients age correlated with MSNA (r =
0.69 and r = 0.62). The regression line of the patients was steeper than
that of controls (P < 0.01) (adapted with permission from [30]).
Based on the pathophysiologic considerations outlined
above it seems logical that an angiotensin-converting en-
zyme (ACE) inhibitor or an Ang II receptor antago-
nist reduce MSNA. Indeed, enalapril and losartan lower
blood pressure and MSNA in CRF patients [26, 34]
(Fig. 4). In the dosages used in our study, the two drugs
are equally effective in their blood pressure lowering
and MSNA-inhibiting effect [34]. This is in contrast to
amlodipine, which reduces blood pressure but increases
MSNA [26]. These studies provide evidence in humans
that centrally located Ang II importantly contributes in
the pathogenesis of this form of hypertension, thereby
confirming the experimental data outlined above.
In both studies, MSNA was only partially suppressed
[26, 34]. Addition of the centrally acting sympatholytic
drug moxonidine to the treatment with an Ang II antag-
onist resulted in a normalization of blood pressure and
MSNA [abstract; Neumann J et al, J Am Soc Nephrol
14:20A, 2003].
Nitric oxide inhibition. Nitric oxide availability is
clearly decreased in humans with advanced CRF, but also
in early renal failure [35, 36]. If this is also the case for
central nervous system nitric oxide, it could result in a
limitation of the central inhibition of sympathetic out-
flow. However, the acute effects of a systemic infusion of
N-monomethyl-L-arginine (L-NMMA), which is a NOS
inhibitor, in humans were an increase in blood pressure
and decrease in MSNA [37], while others found a dose-
dependent effect, sympatho-excitatory at low dosage and
inhibitory at higher dosage [38]. Effects on sympathetic
activity of chronic administration in humans have not
been assessed. However, asymmetrical dimethylarginine
(ADMA), which is an endogenous inhibitor of NOS, ap-
peared to be a strong and independent predictor of over-
all mortality and cardiovascular outcome in hemodialysis
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Fig. 3. Plots of extracellular fluid volume (ECV) and muscle sympa-
thetic nerve activity (MSNA) and ECV and plasma renin activity (PRA)
in chronic renal failure patients (•; N = 7) in normovolemic and hyper-
volemic condition and in healthy volunteers (◦; N = 8) during low and
high sodium diet (adapted with permission from [30]).
patients [39], and is associated with left ventricular di-
mensions [40]. Interestingly, recent data in dialysis pa-
tients show a relationship between norepinephrine and
ADMA levels, suggesting a cause and effect relation [41].
Dialysis regimen. It was already shown that intensify-
ing the dialysis regimen has a profound impact on blood
pressure, presumably by its effect on peripheral vascu-
lar resistance [42–45]. It also results in regression of left
ventricular hypertrophy (LVH) [42]. We have recently
shown that increasing the frequency of hemodialysis from
three to six times weekly results in a decrease in MSNA,
accompanied by a decrease in peripheral resistance [ab-
stract; Zilch O et al, J Am Soc Nephrol 12:280A, 2001].
The MSNA returned to its initial level after the patients
returned after 6 months to the three weekly regimen.
This important finding points to an additional mechanism
for the pathogenesis of sympathetic hyperactivity. Appar-
ently, the intensification of the dialysis regimen results
in the reduction of sympatho-stimulating factor(s) or in
an increase in sympatho-inhibiting factor(s). ADMA, an
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Fig. 4. Changes in mean arterial pressure and muscle sympathetic
nerve activity (MSNA) during intravenous infusion of enalaprilat and
during long-term (approximately 6 weeks) treatment with enalapril in
patients with chronic renal failure (CRF). Blood pressure was decreased
by both long-term treatment with enalapril (P < 0.001) and a short-term
infusion of enalaprilat (P = 0.007). MSNA was decreased by long-term
treatment with enalapril (P < 0.001) and increased by a short-term in-
fusion of enalaprilat (P = 0.005) (with permission from [26]). ACEi is
angiotensin-converting enzyme inhibitor.
inhibitor of NOS, concentrations are increased in
hemodialysis patients, but reduced by hemodialysis treat-
ment [41, 46]. It is very well possible that by increasing
the dosage of hemodialysis more ADMA and possibly
other inhibitors of the nitric oxide system are removed,
ultimately resulting in an inhibition of sympathetic activ-
ity, as outlined above. One study suggested that during
hemodiafiltration ADMA removal was more effective
than during standard hemodialysis [47].
Sleep apnea is a condition associated with sympathetic
hyperactivity. Dialysis patients also often suffer from this
condition. Interestingly, nocturnal hemodialysis has been
shown to reduce the number of sleep apnea periods [48].
The mechanism for this effect is unclear. Whether noc-
turnal hemodialysis reduces MSNA remains to be shown.
Clinical relevance
Is the sympathetic hyperactivity harmful? There is sub-
stantial evidence that it is!
Blood pressure. The importance of sympathetic hy-
peractivity for elevated blood pressure in CRF was al-
ready demonstrated by Schohn et al [49], who found a
profound decline in blood pressure after the ganglion
blocker debrisoquine in hypertensive hemodialysis pa-
tients, whereas it had moderate effect in normotensive
patients. We also found an enhanced blood pressure re-
sponse to the sympatholytic drug clonidine [26]. In PKD
patients, blood pressure correlated with MSNA [31]. In
a group of CRF patients with various primary diseases,
blood pressure reduction during chronic ACE inhibitor
or Ang II antagonist correlated with the decrease of
MSNA [34]. These data support the idea that sympathetic
hyperactivity contributes to the hypertension in CKD
patients.
Cardiovascular outcomes. Sympathetic activity is re-
lated to LVH. Indexes of left ventricular mass correlate
with plasma norepinephrine levels [50]. The presence of
LVH is associated with higher MSNA [51], and cardiac
norepinephrine spill over [52]. CRF patients also show
a positive relation between norepinephrine and LVH
[53]. Both CRF patients not yet on dialysis and those on
dialysis often have LVH, and in end-stage renal disease
(ESRD) patients LVH is associated with poor prognosis
[54–57].
Additionally, sympathetic activity contributes to the
development of other forms of organ damage indepen-
dent of its effect on blood pressure (reviewed in [58,
59]). It is associated with heart failure, arrhythmias, and,
in experimental conditions, with atherogenesis [58, 59].
Plasma norepinephrine was an independent predictor for
all-cause mortality and cardiovascular event in hemodial-
ysis patients without overt heart failure [60] (Fig. 5). It is
likely that sympathetic activation is associated with an
even greater cardiovascular risk in renal patients with
heart failure.
Kidney. Sympathetic nervous system may also be im-
portant in determining rate of progression of kidney func-
tion in CKD patients. Catecholamines have direct effects
that may be relevant for renal damage, including pro-
liferative effects mediated by beta-adrenoceptors or ef-
fects on the function of podocytes, the key cells in the
genesis of glomerular injury. Interestingly, in subtotally
nephrectomized rats a low dose of moxonidine but also
of a and b blockers ameliorates renal damage without
affecting blood pressure [61, 62]. These results are com-
patible with the notion that sympathetic activation via
release of catecholamines promotes progression of kid-
ney damage independently of systemic blood pressure, at
least in this animal model. In normotensive diabetic hu-
mans, moxonidine reduced albuminuria without affecting
blood pressure [63].
Treatment
Sympathetic hyperactivity in CKD can be reduced by
several types of antihypertensive medications. We have
shown that both an ACE inhibitor and an Ang II an-
tagonist can reduce but not normalize MSNA in CRF
patients [26, 34]. Addition of a centrally acting sympa-
tholytic agent moxonidine to chronic treatment with an
Ang II receptor antagonist normalizes blood pressure
and MSNA [abstract; Neumann J et al, J Am Soc Nephrol
14:20A, 2003].
The 123I-metaiodobenzylguanidine technique has been
used to show that an ACE inhibitor reduced cardiac
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Fig. 5. Kaplan-Meier survival curves for all-cause death and cardiovascular events (fatal and nonfatal) in hemodialysis patients below and above
the 75th percentile of plasma norepinephrine. Patients in the highest quartile of plasma norepinephrine showed significant greater mortality and
cardiovascular events (with permission from [60]).
sympathetic activity in essential hypertension, whereas
a calcium channel blocker did not [64]. This parallels our
previous findings in CRF patients that enalapril reduced
MSNA and amlodipine did not [26]. The combination of
an ACE inhibitor and an Ang II antagonist or the addi-
tion of spironolacton to ACE inhibitor may be even more
effective [65, 66]. Carvedilol, but not metoprolol, also re-
duces cardiac norepinephrine spill over in heart failure
patients [67]. Cardiac sympathetic activity and the effects
of treatment have yet to be studied in CKD patients.
Antiadrenergic therapy may be beneficial to hyperten-
sive patients, and also in CKD patients. Treatment aimed
at regression of LVH in essential hypertension is partic-
ularly successful when this includes reduction of sympa-
thetic activity (reviewed in [68]). In CRF patients, ACE
inhibition appeared more effective than calcium channel
blockade in reducing LVH [69]. Conceivably, this differ-
ence is explained by the fact that, in contrast to ACE
inhibition, chronic calcium channel blockade increases
MSNA and cardiac sympathetic activity [26, 64]. Also, in
other studies in CRF patients whether or not on dialysis,
ACE inhibitors appear to be most effective in reducing
LVH [70–72].
ACE inhibition improves prognosis in heart failure. It
is particularly superior to traditional vasodilator therapy
in patients with the highest plasma norepinephrine levels
at baseline [73]. In a retrospective analysis in hemodialy-
sis patients ACE inhibitor use, independently of its effect
on blood pressure, seems to be associated with a dra-
matic reduction in mortality [74]. In CRF patients not on
dialysis, ACE inhibitor therapy also improved survival
rates independently of its effect on blood pressure [75].
A recent study shows that in dialysis patients with dilated
cardiomyopathy addition of carvedilol to the standard
therapy regimen reduces cardiovascular morbidity and
mortality as compared to placebo [76]. All these effects
may be mediated by a reduction of sympathetic activity,
although the reduction of Ang II and aldosterone may
also be important.
Do our patients receive any and enough anti-
adrenergic medication? Recent United States Renal
Dialysis System (USRDS) data of more than 11,000
hemodialysis patients indicate that only half of the popu-
lation was prescribed antihypertensive drugs (an average
of 0.76 drugs per patient), most frequently calcium chan-
nel blockers (35%), followed by ACE inhibitors (14%),
centrally acting drugs (10%), and b blockers in 8.5% [77].
The use of b blockers was associated with improved sur-
vival. A CRF population in Germany received a median
of three antihypertensive drugs per patient, most often di-
uretics (77%), followed by ACE inhibitors/Ang II recep-
tor antagonists (64%), calcium channel blockers (58%),
b blockers (40%), and centrally acting agents (29%) [78].
In a more recent study, more than 90% of patients were on
an ACE inhibitor or Ang II receptor antagonist [79]. In a
CRF population in Canada 34% received a b blocker and
64.5% an ACE inhibitor or an Ang II receptor antago-
nist [80]. In the Dialysis Outcomes and Practice Patterns
Study (DOPPS) population only a minority of patients
were on an ACE inhibitor, Ang II antagonist or b blocker
[81]. Finally, in patients admitted to the hospital because
of myocardial infarction, patients with various degree of
CRF were less likely to be treated with an ACE inhibitor
or b blocker than patients with normal renal function
[82].
So, it is clear that there are therapies available to re-
duce sympathetic activity in CKD patients, but that not
all patients receive antiadrenergic agents. It seems safe
to say that based on the pathophysiology outlined above
that an ACE inhibitor or an Ang II receptor antagonist
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should be the cornerstone of treatment, combined with
diuretics (or ultrafiltration in dialysis patients) to main-
tain normovolemia. Because sympathetic hyperactivity is
not normalized in this way, the addition of a b blocker or a
centrally acting sympatholytic agent may be beneficial to
the patient. Indeed, in CRF patients the ACE inhibitors
and Ang II receptor antagonists have been accepted as
first-choice therapy both in Europe and the United States
[83, 84]. Both Guidelines Committees recognized that in
CRF patients often a third agent is necessary to obtain
normotension. A recent study in CRF patients (mean cre-
atinine clearance 28 ± 12 mL/min) showed that adding of
the centrally acting agent moxonidine to standard ther-
apy (including an ACE inhibitor or Ang II receptor an-
tagonist) was safe [79].
Presently, many issues need to be resolved. For in-
stance, it is not known which class or combination of
classes is most effective in reducing sympathetic hyper-
activity and has the greatest effect on cardiovascular and
renal prognosis. Experimental evidence suggests that not
all Ang II receptor antagonists are equally effective in
reducing sympathetic activity at the central and periph-
eral level [85]. Third generation beta-blockers, such as
carvedilol and nebivolol, seem to have more protective
effects than traditional b blockers, possibly by their stimu-
lation of nitric oxide release [67, 86]. Further, in a recent
study in an animal model of heart failure, simvastatine
appears to have a sympatholytic effect [87]. Whether this
class of agents also reduces sympathetic activity in hu-
mans has not been investigated. It is not known whether
agents that reduce MSNA also reduce cardiac sympa-
thetic activity to the same extent. Which patients have the
highest risks? For instance, is there a relation between a
specific renal diagnosis and risk? Do normotensive CKD
patients also benefit from this kind of therapy? If the
state of nitric oxide deficiency characteristic for CRF in-
deed means that even normal sympathetic activity may
cause harm to our patients, these patients might bene-
fit from this treatment as well. In anephric patients, who
have undetectable plasma renin levels, normal MSNA
and usually normal blood pressure, an ACE inhibitor also
reduced blood pressure [25, 88]. All these issues need to
be addressed in clinical trials.
CONCLUSION
Sympathetic activity is increased in hypertensive pa-
tients with renal parenchymal disease. It is “inappro-
priately” increased for the volume status. Recent data
indicate that sympathetic activity is associated with mor-
tality and poor cardiovascular outcomes in CRF patients.
It may also affect the progression of renal failure. Some
authors consider it a cardiovascular and renal risk factor
[89, 90]. We support this view. However, properly de-
signed clinical trials are needed to establish the effects of
specific antiadrenergic therapy in CRF patients on car-
diovascular and renal end points.
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